Company: CRISPR Therapeutics
Job title: Senior Director
Julianne Bruno currently leads CRISPR Tx’s lead program in hemoglobinopathies focused on beta-thalassemia and sickle cell disease. In her previous role in New Product Planning at CRISPR, Julianne led the development of commercial launch strategy across both the hemoglobinopathy and I/O portfolio. Before joining CRISPR, Julianne worked at McKinsey & Company where she was a leader in the biotech practice and served a number of biotechnology companies on a wide range of commercial topics. Julianne received her MBA from The Wharton School and also holds an A.B. from Princeton University.
Understanding Key Commercial Considerations for a Hemoglobinopathy Gene Therapy Launch 8:45 am
Exploring specific factors to consider for sickle cell disease and β-thalassemia programs Discussing appropriate market access strategies to ensure patients receive the therapyRead more
day: Day One